In case the failure to fulfill CGMP ends in the distribution of a drug that does not give the reward as labeled simply because, as an example, it's way too minimal active ingredient, the company could subsequently remember that products.The company can also be registering APIs it makes in China, with programs to supply them to the Chinese market pl